Abstract
Lone atrial fibrillation is a set of heterogeneous disorders grouped together due to our limited understanding of their pathophysiology. Rate control and rhythm control are two strategies used to treat atrial fibrillation but neither has shown improvement in mortality. Therefore, the goal of treatment in patients with lone atrial fibrillation is to improve health related quality of life. Anti-arrhythmic medications are not well studied in lone atrial fibrillation patient population in randomized controlled fashion. However, inferences can be made from trials that mainly included paroxysmal atrial fibrillation patients. Anti-arrhythmic medications are useful in maintenance of sinus rhythm and probably improve quality of life in lone atrial fibrillation.
Keywords: Atrial fibrillation, anti-arrhythmic drugs, healthcare related quality of life.
Current Pharmaceutical Design
Title:Utility of Anti-Arrhythmic Medications in ‘Lone Atrial Fibrillation’
Volume: 21 Issue: 5
Author(s): Ramanan Kumareswaran and Paul Dorian
Affiliation:
Keywords: Atrial fibrillation, anti-arrhythmic drugs, healthcare related quality of life.
Abstract: Lone atrial fibrillation is a set of heterogeneous disorders grouped together due to our limited understanding of their pathophysiology. Rate control and rhythm control are two strategies used to treat atrial fibrillation but neither has shown improvement in mortality. Therefore, the goal of treatment in patients with lone atrial fibrillation is to improve health related quality of life. Anti-arrhythmic medications are not well studied in lone atrial fibrillation patient population in randomized controlled fashion. However, inferences can be made from trials that mainly included paroxysmal atrial fibrillation patients. Anti-arrhythmic medications are useful in maintenance of sinus rhythm and probably improve quality of life in lone atrial fibrillation.
Export Options
About this article
Cite this article as:
Kumareswaran Ramanan and Dorian Paul, Utility of Anti-Arrhythmic Medications in ‘Lone Atrial Fibrillation’, Current Pharmaceutical Design 2015; 21 (5) . https://dx.doi.org/10.2174/1381612820666140825145357
DOI https://dx.doi.org/10.2174/1381612820666140825145357 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Drug Therapy of Neuropathic Pain: Current Developments and Future Perspectives
Current Drug Targets Myocardial Contrast Echocardiography: Role in Clinical Cardiology
Current Vascular Pharmacology Targeting Transient Receptor Potential Canonical Channels for Diseases of the Nervous System
Current Drug Targets Recent Patents on Epilepsy Genetics
Recent Patents on DNA & Gene Sequences Assessing Cardiovascular Risk in Patients with Diabetes: An Update
Current Cardiology Reviews New Approaches for the Treatment of Chagas Disease
Current Drug Targets Targeting the Toll-System in Cardiovascular Sciences
Recent Patents on Inflammation & Allergy Drug Discovery Inhibitory Effect of PD-1/PD-L1 and Blockade Immunotherapy in Leukemia
Combinatorial Chemistry & High Throughput Screening Targeting Potassium Channels: New Advances in Cardiovascular Therapy
Recent Patents on Cardiovascular Drug Discovery Gene Therapy Approaches for Cardiovascular Diseases
Current Gene Therapy Acute Cardioembolic Cerebral Infarction: Answers to Clinical Questions
Current Cardiology Reviews Sex-Gender Differences in Diabetes Vascular Complications and Treatment
Endocrine, Metabolic & Immune Disorders - Drug Targets microRNA as Biomarkers and Regulator of Cardiovascular Development and Disease
Current Pharmaceutical Design Beta-Blocker Therapy for Septic Cardiac Shock: Fiction Or Realism?
Current Drug Therapy The Potential Role of Erythropoietin as a Pleiotropic Agent in Post-cardiac Arrest Syndrome
Current Pharmaceutical Design Clinical Features of Scleroderma-Like Disorders: A Challenge for the Rheumatologist
Current Rheumatology Reviews Aldosteronism in Heart Failure: A Proinflammatory / Fibrogenic Cardiac Phenotype. Search for Biomarkers and Potential Drug Targets
Current Drug Targets Pleiotropic Effect of Statins as Antioxidants on Cardiac Hypertrophy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Levosimendan: A New Inodilatory Drug for the Treatment of Decompensated Heart Failure
Current Pharmaceutical Design State of the Heart: CMR in Coronary Artery Disease
Current Medical Imaging